anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, continues to elude complete comprehension of its pathological underpinnings. Recent focus on inflammation in ALS pathogenesis prompts this investigation into the genetic correlation and potential causal relationships between circulating inflammatory proteins and ALS.
METHODS: Genome-wide association study (GWAS) data encompassing 91 circulating inflammatory protein measures from 14,824 individuals of European ancestry, alongside records from 27,205 ALS cases and 110,881 controls, were employed. Assessment of genetic correlation and overlap utilized LD score regression (LDSC), high-definition likelihood (HDL), and genetic analysis integrating pleiotropy and annotation (GPA) methodologies. Identification of shared genetic loci involved pleiotropy analysis, functional mapping and annotation (FUMA), and co-localization analysis. Finally, Mendelian randomization was applied to probe causal relationships between inflammatory proteins and ALS.
RESULTS: Our investigation revealed significant genetic correlation and overlap between ALS and various inflammatory proteins, including C-C motif chemokine 28, Interleukin-18, C-X-C motif chemokine 1, and Leukemia inhibitory factor receptor (LIFR). Pleiotropy analysis uncovered shared variations at specific genetic loci, some of which bore potential harm. Mendelian randomization analysis suggested that alterations in specific inflammatory protein levels, notably LIFR, could impact ALS risk.
CONCLUSIONS: Our findings uncover a genetic correlation between certain circulating inflammatory proteins and ALS, suggesting their possible causal involvement in ALS pathogenesis. Moreover, the identification of LIFR as a crucial protein may yield new insights into ALS pathomechanisms and offer a promising avenue for therapeutic interventions. These discoveries provide novel perspectives for advancing the comprehension of ALS pathophysiology and exploring potential therapeutic avenues.
Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
In the preparation of a vaccine for immunizing swine against hog-cholera, hog-cholera virus is attenuated by transfer through, say, 13 to 15 animals other than swine, e.g. rabbits, a saline suspension of the animal tissue, e.g. spleen, or defibrinated blood, is parentally administered to a hog, and after a temperature rise of the hog, the blood and/or tissue harbouring the attenuated virus, e.g. spleen, liver, or testes are separated, and the vaccine isolated therefrom.  Thus, the blood may be defibrinated and rendered sterile by the addition of phenol, or the tissue is ground and screened.  It may then be dried for subsequent reconstitution, or be buffered with an isotonic solution or admixed with glycine, lactose, &c.  Other active substances may be added; thus, the defibrinated blood, or blood sera, or ground tissue may be made up with crystal violet and glycerol, or antiseptics such as phenol, other dyes such as methylene blue or acriflavine, sulphamethazine, suphamerazine, sulphaquinoxaline, antibiotics, gammaglobulin, &c. may be added. The product may be administered orally or parentally, if desired in conjunction with anti-cholera serum.
OBJECTIVE: This study investigates the prevalence of pathogenic variants in the mechanistic target of rapamycin (mTOR) pathway in surgical specimens of malformations of cortical development (MCDs) and cases with negative histology. The study also aims to evaluate the predictive value of genotype-histotype findings on the surgical outcome.
METHODS: The study included patients with drug-resistant focal epilepsy who underwent epilepsy surgery. Cases were selected based on histopathological diagnosis, focusing on MCDs and negative findings. We included brain tissues both as formalin-fixed, paraffin-embedded (FFPE) or fresh frozen (FF) samples. Single-molecule molecular inversion probes (smMIPs) analysis was conducted, targeting the MTOR gene in FFPE samples and 10 genes within the mTOR pathway in FF samples. Correlations between genotype-histotype and surgical outcome were examined.
RESULTS: We included 78 patients for whom we obtained 28 FFPE samples and 50 FF tissues. Seventeen pathogenic variants (22 %) were identified and validated, with 13 being somatic within the MTOR gene and 4 germlines (2 DEPDC5, 1 TSC1, 1 TSC2). Pathogenic variants in mTOR pathway genes were exclusively found in FCDII and TSC cases, with a significant association between FCD type IIb and MTOR genotype (P = 0.003). Patients carrying mutations had a slightly better surgical outcome than the overall cohort, however it results not significant. The FCDII diagnosed cases more frequently had normal neuropsychological test, a higher incidence of auras, fewer multiple seizure types, lower occurrence of seizures with awareness impairment, less ictal automatisms, fewer Stereo-EEG investigations, and a longer period long-life of seizure freedom before surgery.
SIGNIFICANCE: This study confirms that somatic MTOR variants represent the primary genetic alteration detected in brain specimens from FCDII/TSC cases, while germline DEPDC5, TSC1/TSC2 variants are relatively rare. Systematic screening for these mutations in surgically treated patients' brain specimens can aid histopathological diagnoses and serve as a biomarker for positive surgical outcomes. Certain clinical features associated with pathogenic variants in mTOR pathway genes may suggest a genetic etiology in FCDII patients.
Stable chest pain is one of the most common complaints by patients. However, about 50% of patients referred for catheter coronary angiograms do not have obstructive coronary artery disease (CAD). In the United Kingdom (UK), one very large population study showed that \~70% of patients did not have a cause for the chest pain diagnosed within 6 months of presentation. Furthermore, the study further showed that this group of patients had a significantly higher risk of major adverse cardiovascular events (MACE) compared to patients without chest pain. It is now understood that the two major causes of cardiac chest pain with non obstructive CAD (also known as Ischaemia with Non Obstructive Coronary Arteries (INOCA)) are coronary microvascular dysfunction (CMD) and the other is coronary vasospasm. CMD and coronary vasospasm have been shown in one randomised controlled study to comprise 52% and 17% of all patients with INOCA. However, therapies for CMD are lacking and has been highlighted as a major area of need.
The Ataxia Global Initiative (AGI) is a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias. The next-generation sequencing (NGS) working group of the AGI aims to improve methods, platforms, and international standards for ataxia NGS analysis and data sharing, ultimately allowing to increase the number of genetically ataxia patients amenable for natural history and treatment trials. Despite extensive implementation of NGS for ataxia patients in clinical and research settings, the diagnostic gap remains sizeable, as approximately 50% of patients with hereditary ataxia remain genetically undiagnosed. One current shortcoming is the fragmentation of patients and NGS datasets on different analysis platforms and databases around the world. The AGI NGS working group in collaboration with the AGI associated research platforms-CAGC, GENESIS, and RD-Connect GPAP-provides clinicians and scientists access to user-friendly and adaptable interfaces to analyze genome-scale patient data. These platforms also foster collaboration within the ataxia community. These efforts and tools have led to the diagnosis of > 500 ataxia patients and the discovery of > 30 novel ataxia genes. Here, the AGI NGS working group presents their consensus recommendations for NGS data sharing initiatives in the ataxia field, focusing on harmonized NGS variant analysis and standardized clinical and metadata collection, combined with collaborative data and analysis tool sharing across platforms.
Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
Participants randomized to LI arm will receive PN to social service needs + culturally and linguistically tailored cancer education materials. All individuals will complete a survey at baseline, 3 months, and 6 months. Once a participant randomized to the LI arm completes the 6-month survey, they will have the option to receive all navigational support provided by CHWs to individuals randomized to the PN arm.
AD is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. However, people with AD do not all develop the same infections. For example, some people with AD who receive the smallpox vaccine develop a life-threatening condition known as eczema vaccinatum (EV). This study focuses on individuals with AD who also have a history of eczema herpeticum (ADEH+), a condition similar to EV. It is unlikely that the differences in the development of skin infections are due to differences in viral exposure, and instead due to differences in each individual's response to viruses. The purpose of this study is to determine the genetic pathways which are responsible for the development of viral skin infections in people with AD.

Participants in this study will also be enrolled in the ADVN Biomarker Registry Study. There will be only one clinical visit for this study at which blood and/or skin samples may be collected. The samples will then have high-throughput genotyping to define genetic markers in individuals susceptible to viral infections.
Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
PROBLEM TO BE SOLVED: To obtain the subject new compound, having inhibiting actions on the production or secretion of a tumor necrosis factor and useful as a therapeutic agent for cachexia, spetic shocks, multiple organ failure, chronic articular rheumatism, inflammatory intestinal diseases, etc. SOLUTION: This compound is represented by formula I (R<1> to R<5> are each H, a halogen, an alkyl, etc.; R<6> is an aryl, etc.; R<7> is H, an aryl, etc.), e.g. 1-[4-(2-dithienylmethylene)piperidino]phthalazine. The compound represented by formula I is obtained by reacting a phthalazine derivative represented by formula II (X is a halogen) with a pieridine derivative represented by formula III in an inert organic solvent at 0-200 deg.C and providing a halogenated piperidinylphthalazine derivative represented by formula IV which affords a compound included in the compound represented by formula I in which the R<1> is the halogen. The resultant compound represented by formula IV is then hydrogenated in the presence of a catalyst to provide the compound represented by formula I in which R<1> is the H. The compound is effective even in treating multiple sclerosis, arthrosis deformans.  Behcet's disease, systemic lupus erythematosus, rejection and the time of bone marrow transplantation, malaria, AIDS, etc., besides the diseases described above.
The study will be conducted as an interventional N-of-1 study with an A1-B-A2 design of 8 weeks per study period. Prior to the study, participants will be screened and if eligible, will complete a number of baseline questionnaires to provide an overview of their typical eating and lifestyle-related behaviours, and general health. A second visit prior to the start of the study will then be arranged, where participants will undergo a semi-structured interview. Responses from the interview, in combination with their baseline questionnaire responses, will be used to identify factors specific to the participant that show some degree of variability. These will form the basis of the semi-personalised questionnaires delivered via the wrist-worn PRO-Diary device for the duration of the study. During the study, participants will visit the institute in a fasted state every 4 weeks (7 visits total), in order to provide a blood sample for assessment of cholesterol levels and for assessment of biomarkers of wholegrains intake. At the first visit, participants will receive the wireless blood pressure monitor and PRO-Diary wrist device programmed with twice-daily questionnaires at times convenient to the participant. After 2 weeks and every 4 weeks thereafter, participants will be sent a link by email to complete a 24-hour dietary recall. After 8 weeks, participants will begin the intervention phase and receive wholegrains equivalent to 3 portions a day and 1 portion of unsalted nuts per day for the following 8 weeks. Participants will be able to choose from a variety of wholegrain products commonly available at supermarkets. They will also receive dietary advice to follow a Dietary Approaches to Stop Hypertension (DASH) diet aimed at lowering blood pressure. All other measures will continue as previously. At week 16, the wholegrains and nuts will be withdrawn and participants will be followed up for a further 8 weeks. At their final visit to the institute, they will complete the same validated questionnaires as at baseline. Results from the study will be analysed using N-of-1 dynamic modelling to analyse trends over time and determine whether any personalised factors significantly affected adherence to intervention or blood pressure response.
The present invention relates to a prescription of novle channel activating ointment and a preparation method thereof. The prescription is prepared from 14 Chinese-medicinal materials, such as Sanguis Draconis, angelica, hemlock parsley, safflower, frankincense, himalayan teasel root, notopterygium root, cassia bark, etc. After being fixed uniformly, the Chinese-medicinal materials are percolated by ethanol, and the percolate is concentrated into extract. Then a substrate is prepared from rubber, rosin, etc., and ointment coating, segment cutting and line covering are carried out to obtain the ointment. The preparation method is scientific and reasonable, and the prepared ointment has the advantages of convenient use and no influence on joint motion. The ointment has the functions of blood circulation activation, tissue regeneration, blood nourishment and replenishment, channel warming, numbness removing, collaterals activation, blood stasis dissipation, wind expelling and cold clearing and qi benefiting. The ointment has unique therapeutic effect on curing symptoms of later period of athletic injury, chronic strain combined with wind-cold warm numbness, old damage, wind-cold warm numbness, etc.
The most of interventional studies on nutrition consultation have generally emphasized on the extent to which the diet composition can prevent chronic diseases or provide improvement. Although dietitians play an important role in health education for the primary prevention of chronic disease, their individuals dietary consultation results are mostly focused on weight loss and blood glucose control. However, the effectiveness of nutrition consultation on the prevention of chronic diseases, such as hyperlipidemia, hypertension and cardiovascular diseases, has few been studied. The effectiveness of dietary instructions provided to individuals by dietitians in primary health care institutes is yet to be validated with significant evidence. In addition, nutrition consultation methods, processes, and influencing factors on its results are seldom discussed. Therefore, this study aims to investigate the frequency of personalized nutrition counseling's effect on individual cardiovascular risk factors. The study collected1 10 to 150 cases data who aimed to prevent or improve chronic diseases and had completed eight times individualized nutrition consultations from Bon Vivant Health Lifestyle Management Center, and the pre- and post-consultation data, including a regular blood test, blood glucose, blood lipid, liver panel, and inflammatory factors, will be analyzed. Blood were drawn before and after the first and the last time consultation for biochemical tests; blood pressure and body composition was also measured for comparison. The enrolled cases will be classified into two groups according to the subjects' duration of consultation: those who completed the consultation and subsequent tests in \>24 weeks were in the control group, whereas those who completed the consultation and subsequent tests in \<24 weeks were in the test group. The effectiveness of nutrition consultation toward managing cardiovascular disease risk factors and its correlation with the subjects' frequency of following the consultations was analyzed using the pre- and post-consultation data. It was found that personalized nutrition consultation significantly improved the subjects' risk factors of cardiovascular diseases, and that the treatment group showed a greater improvement than the control group which who require over 24 weeks to complete all consultation sessions.
Teratogenic Effects: Pregnancy Category C. Propafenone HCl has been shown to be embryotoxic (decreased survival) in rabbits and rats when given in oral maternally toxic doses of 150 mg/kg/day (about three times the maximum recommended human dose [MRHD] on a mg/m² basis) and 600 mg/kg/day (about six times the MRHD on a mg/m² basis), respectively. Although maternally tolerated doses (up to 270 mg/kg/day, about three times the MRHD on a mg/m² basis) produced no evidence of embryotoxicity in rats, post-implantation loss was ele­vated in all rabbit treatment groups (doses as low as 15 mg/kg/day, about 1/3 the MRHD on a mg/m² basis). There are no adequate and well-controlled studies in pregnant women. Propafenone ER capsules (propafenone hydrochloride) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Non-Teratogenic Effects: In a study in which female rats received daily oral doses of propafenone HCl from mid-gestation through weaning of their offspring, doses as low as 90 mg/kg/day (equivalent to the MRHD on a mg/m² basis) produced increases in maternal deaths. Doses of 360 or more mg/kg/day (four or more times the MRHD on a mg/m² basis) resulted in reductions in neonatal survival, body weight gain and physiological development.
The invention belongs to the field of traditional Chinese medicine formulas and particularly relates to a traditional Chinese medicine formula for treating stomach multiple ulcer. The traditional Chinese medicine formula comprises following raw materials by weight: 10-15 g of codonopsis pilosula, 8-12 g of parched white atractylodes rhizome, 10-15 g of wolfiporia extensa, 5-8 g of rhizoma zingiberis praeparatum, 10-20 g of stir-fried cuttlebone, 8-12 g of dried orange peel, 3-5 g of fructus amomi, 10-15 g of pseudobulbus cremastrae seu pleiones, 10-15 g of five-leaf akebia fruit, 5-10 g of rosa multiflora, 8-12 g of radix rhapontici, 10-15 g of herba agrimoniae, 8-12 g of fructus forsythiae, 3-5 g of honey-fried herba ephedrae and 5-8 g of radix platycodonis. The traditional Chinese medicine has advantages of simple composition, a low price, a short course of treatment, good curative effects, a high curative rate, and the like. By stasis based on that one week of medicine taking is adopted as a course of treatment, the effective rate is 100%, the curative rate is 96% and the improving rate is 6%. The raw materials are abundant. A preparing method of the traditional Chinese medicine formula is simple, convenient and feasible.
A low-viscosity, high pH antacid composition comprising: sodium bicarbonate, potassium bicarbonate; calcium carbonate, sweetener, and water. The concentration of sodium bicarbonate in the composition of the invention is preferably in the range of from 1% to 3% by weight. The concentration of potassium bicarbonate in the composition of the invention is preferably in the range of from 0.5% to 1% by weight. The concentration of calcium carbonate in the composition of the invention is preferably in the range of from 0.25% to 1% by weight. The concentration of sweetener in the composition of the invention is preferably in the range of from 0.02% to 0.04% by weight. The remainder of the composition is a low viscosity transport agent, such as water. Additionally, stabilizers may be added and flavoring/coloring agents may be added.
Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
Provided are a method for preparing a multifunctional intestinal diagnosis and treatment formulation, and a product thereof. The present invention comprises an intestine-targeting photoacoustic imaging contrast agent and a preparation method therefor, a PET/ultrasound multifunctional intestinal contrast agent and a preparation method therefor, as well as a  18 F-fluorocarbon compound and gold nanorod-containing M2 macrophage probe and a preparation method therefor. In particular, the multifunctional intestinal diagnosis and treatment formulation product has multifunctional probes for PET imaging, ultrasound imaging, and photothermal therapy, accurate tumor localization and high sensitivity long period imaging can be simultaneously performed, and the targeting imaging efficiency of a probe on a tumor is improved. Macrophages serve as a drug carrier "reservoir". Carrier enrichment at a tumor site is enhanced, and chitosan is able to effectively attach to the surface of intestinal mucosa. An  18 F-type nuclide serves as a PET imaging agent. A fluorocarbon compound serves as an ultrasound contrast agent. Gold nanorods have a photothermal effect, and have a therapeutic effect on the tumor site.